{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:39:58Z","timestamp":1791333598174,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["R\u00e9silience COVID-19: ANR-21-COVR-0022"],"award-info":[{"award-number":["R\u00e9silience COVID-19: ANR-21-COVR-0022"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with auto-antibodies neutralizing type I interferons (anti-IFN auto-Abs) are at risk of severe forms of coronavirus disease 19 (COVID-19). The chest computed tomography (CT) scan characteristics of critically ill COVID-19 patients harboring these auto-Abs have never been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bicentric ancillary study of the ANTICOV study (observational prospective cohort of severe COVID-19 patients admitted to the intensive care unit (ICU) for hypoxemic acute respiratory failure between March 2020 and May 2021) on chest CT scan characteristics (severity score, parenchymal, pleural, vascular patterns). Anti-IFN auto-Abs were detected using a luciferase neutralization reporting assay. Imaging data were collected through independent blinded reading of two thoracic radiologists of chest CT studies performed at ICU admission (\u00b1 72 h). The primary outcome measure was the evaluation of severity by the total severity score (TSS) and the CT severity score (CTSS) according to the presence or absence of anti-IFN auto-Abs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred thirty-one critically ill COVID-19 patients were included in the study (mean age 59.5 \u00b1 12.7 years; males 74.6%). Day 90 mortality was 29.5% (\n                      <jats:italic>n<\/jats:italic>\n                      = 72\/244). There was a trend towards more severe radiological lesions in patients with anti-IFN auto-Abs than in others, not reaching statistical significance (median CTSS 27.5 (21.0\u201334.8) versus 24.0 (19.0\u201330.0),\n                      <jats:italic>p<\/jats:italic>\n                      = 0.052; median TSS 14.5 (10.2\u201317.0) versus 12.0 (9.0\u201315.0),\n                      <jats:italic>p<\/jats:italic>\n                      = 0.070). The extra-parenchymal evaluation found no difference in the proportion of patients with pleural effusion, mediastinal lymphadenopathy, or thymal abnormalities in the two populations. The prevalence of pulmonary embolism was not significantly different between groups (8.7% versus 5.3%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.623,\n                      <jats:italic>n<\/jats:italic>\n                      = 175).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was no significant difference in disease severity as evaluated by chest CT in severe COVID-19 patients admitted to the ICU for hypoxemic acute respiratory failure with or without anti-IFN auto-Abs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-023-01606-4","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T22:21:07Z","timestamp":1703197267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chest Computed Tomography Characteristics of Critically Ill COVID-19 Patients with Auto-antibodies Against Type I Interferons"],"prefix":"10.1007","volume":"44","author":[{"given":"Baptiste","family":"Lafont Rapnouil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Zaarour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Arrestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Peiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Moncomble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lodie","family":"Parfait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Bella\u00efche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Mekontso Dessap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Mule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4320","authenticated-orcid":false,"given":"Nicolas","family":"de Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"1606_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00134-020-06294-x","volume":"47","author":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators","year":"2021","unstructured":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47:60\u201373.","journal-title":"Intensive Care Med"},{"key":"1606_CR2","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","volume":"370","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570.","journal-title":"Science"},{"key":"1606_CR3","doi-asserted-by":"publisher","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","volume":"6","author":"T Asano","year":"2021","unstructured":"Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6:eabl4348.","journal-title":"Sci Immunol"},{"key":"1606_CR4","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.","journal-title":"Science"},{"key":"1606_CR5","unstructured":"Bastard P, Gervais A, Voyer TL, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths. Sci Immunol. 2021;19:eabl4340."},{"key":"1606_CR6","doi-asserted-by":"publisher","first-page":"e2200413119","DOI":"10.1073\/pnas.2200413119","volume":"119","author":"J Manry","year":"2022","unstructured":"Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci USA. 2022;119:e2200413119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1606_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijid.2023.03.011","volume":"130","author":"X Wang","year":"2023","unstructured":"Wang X, Tang Q, Li H, Jiang H, Xu J, Bergquist R, et al. Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis. Int J Infect Dis. 2023;130:147\u201352.","journal-title":"Int J Infect Dis"},{"key":"1606_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10875-023-01512-9","volume":"43","author":"Q Philippot","year":"2023","unstructured":"Philippot Q, Fekkar A, Gervais A, Le Voyer T, Boers LS, Conil C, et al. Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life-threatening COVID-19 pneumonia. J Clin Immunol. 2023;43:1093\u2013103.","journal-title":"J Clin Immunol."},{"key":"1606_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1126\/science.adf2350","volume":"378","author":"M Leslie","year":"2022","unstructured":"Leslie M. A viral arsenal. Science. 2022;378:128\u201331.","journal-title":"Science"},{"key":"1606_CR10","doi-asserted-by":"publisher","first-page":"e20201241","DOI":"10.1084\/jem.20201241","volume":"217","author":"B Israelow","year":"2020","unstructured":"Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med. 2020;217:e20201241.","journal-title":"J Exp Med"},{"key":"1606_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13613-022-01095-5","volume":"12","author":"R Arrestier","year":"2022","unstructured":"Arrestier R, Bastard P, Belmondo T, Voiriot G, Urbina T, Luyt C-E, et al. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study. Ann Intensive Care. 2022;12:121.","journal-title":"Ann Intensive Care"},{"key":"1606_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718\u201324.","journal-title":"Science"},{"key":"1606_CR13","doi-asserted-by":"publisher","first-page":"eabh2624","DOI":"10.1126\/scitranslmed.abh2624","volume":"13","author":"MGP Van Der Wijst","year":"2021","unstructured":"Van Der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624.","journal-title":"Sci Transl Med"},{"key":"1606_CR14","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/thoraxjnl-2020-215383","volume":"76","author":"BK Tan","year":"2021","unstructured":"Tan BK, Mainbourg S, Friggeri A, Bertoletti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76:970\u20139.","journal-title":"Thorax"},{"key":"1606_CR15","doi-asserted-by":"publisher","first-page":"E262","DOI":"10.1148\/radiol.2021204522","volume":"299","author":"JP Kanne","year":"2021","unstructured":"Kanne JP, Bai H, Bernheim A, Chung M, Haramati LB, Kallmes DF, et al. COVID-19 Imaging: what we know now and what remains unknown. Radiology. 2021;299:E262\u201379.","journal-title":"Radiology"},{"key":"1606_CR16","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"JC Marshall","year":"2020","unstructured":"Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192\u20137.","journal-title":"Lancet Infect Dis"},{"key":"1606_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"1606_CR18","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1007\/s00330-020-06817-6","volume":"30","author":"K Li","year":"2020","unstructured":"Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020;30:4407\u201316.","journal-title":"Eur Radiol"},{"key":"1606_CR19","doi-asserted-by":"publisher","first-page":"e200047","DOI":"10.1148\/ryct.2020200047","volume":"2","author":"R Yang","year":"2020","unstructured":"Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19. Radiol Cardiothorac Imaging. 2020;2:e200047.","journal-title":"Radiol Cardiothorac Imaging"},{"key":"1606_CR20","doi-asserted-by":"publisher","first-page":"e20211387","DOI":"10.1084\/jem.20211387","volume":"219","author":"A Puel","year":"2022","unstructured":"Puel A, Bastard P, Bustamante J, Casanova J-L. Human autoantibodies underlying infectious diseases. J Exp Med. 2022;219:e20211387.","journal-title":"J Exp Med"},{"key":"1606_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","volume":"603","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Bastard P, Human Genetic Effort COVID, Karbuz A, Gervais A, Tayoun AA, et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587\u201398.","journal-title":"Nature"},{"key":"1606_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1146\/annurev-immunol-101921-050835","volume":"41","author":"HC Su","year":"2023","unstructured":"Su HC, Jing H, Zhang Y, Casanova J-L. Interfering with interferons: a critical mechanism for critical COVID-19 pneumonia. Annu Rev Immunol. 2023;41:561\u201385.","journal-title":"Annu Rev Immunol"},{"key":"1606_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13073-023-01173-8","volume":"15","author":"D Matuozzo","year":"2023","unstructured":"Matuozzo D, Talouarn E, Marchal A, Zhang P, Manry J, Seeleuthner Y, et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med. 2023;15:22.","journal-title":"Genome Med"},{"key":"1606_CR24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","volume":"9","author":"MF Osuchowski","year":"2021","unstructured":"Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9:622\u201342.","journal-title":"Lancet Respir Med"},{"key":"1606_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1148\/radiology.189.3.8234692","volume":"189","author":"M Remy-Jardin","year":"1993","unstructured":"Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology. 1993;189:693\u20138.","journal-title":"Radiology"},{"key":"1606_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","volume":"131","author":"CT Esmon","year":"2005","unstructured":"Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417\u201330.","journal-title":"Br J Haematol"},{"key":"1606_CR27","doi-asserted-by":"publisher","first-page":"12081","DOI":"10.3390\/ijms222112081","volume":"22","author":"Y Higashikuni","year":"2021","unstructured":"Higashikuni Y, Liu W, Obana T, Sata M. Pathogenic basis of thromboinflammation and endothelial injury in COVID-19: current findings and therapeutic implications. IJMS. 2021;22:12081.","journal-title":"IJMS"},{"key":"1606_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","volume":"74","author":"P Bastard","year":"2022","unstructured":"Bastard P, Zhang Q, Zhang S-Y, Jouanguy E, Casanova J-L. Type I interferons and SARS-CoV-2: from cells to organisms. Curr Opin Immunol. 2022;74:172\u201382.","journal-title":"Curr Opin Immunol"},{"key":"1606_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","volume":"43","author":"A Marx","year":"2021","unstructured":"Marx A, Yamada Y, Simon-Keller K, Schalke B, Willcox N, Str\u00f6bel P, et al. Thymus and autoimmunity. Semin Immunopathol. 2021;43:45\u201364.","journal-title":"Semin Immunopathol"},{"key":"1606_CR30","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","volume":"3","author":"A Meager","year":"2006","unstructured":"Meager A, Visvalingam K, Peterson P, M\u00f6ll K, Murum\u00e4gi A, Krohn K, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3:e289.","journal-title":"PLoS Med"},{"key":"1606_CR31","doi-asserted-by":"publisher","first-page":"676236","DOI":"10.3389\/fimmu.2021.676236","volume":"12","author":"J Srinivasan","year":"2021","unstructured":"Srinivasan J, Lancaster JN, Singarapu N, Hale LP, Ehrlich LIR, Richie ER. Age-related changes in thymic central tolerance. Front Immunol. 2021;12:676236.","journal-title":"Front Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01606-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01606-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01606-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:18:22Z","timestamp":1706674702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01606-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01606-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3029654\/v1","asserted-by":"object"}]},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Comit\u00e9 de Protection des Personnes Nord-Ouest IV (N\u00b0 EudraCT\/ID-RCB: 2020-A03009-30).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all patients or their relatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"15"}}